can type 1 diabetics use glp-1 and GIP in Diabetes Therapy: A Time for Reappraisal? 🚨 Big news for people

For the broader muscle-retention strategy, read our guide to muscle loss on GLP-1 drugs

These results come from large, longitudinal clinical studies, not social media testimonials or short-term use

Considering the promising results of the SURPASS and SURMOUNT trials, what additional factors or challenges must researchers address before adopting tirzepatide for conditions beyond Type 2 diabetes, such as non-alcoholic fatty liver disease (NAFLD)

The binding of prorenin to PRR triggers the phosphorylation of mitogen-activated protein kinases/extracellular regulated kinases 1/2 (MAPK/ERK1/2), which is demonstrated to be an ANG II-independent mechanism involved in the development of diabetic nephropathy ( The ANGIV/AT4/IRAP cascade: ANG IV (derived from the metabolization of ANG II through aminopeptidases A and N) binds the AT4 receptor, which has been identified as the insulin-regulated aminopeptidase (IRAP), but the role of this pathway in the blood pressure and renal regulation is still uncertain ( These new axes have raised great interest because their targeting could provide novel therapeutic strategies for hypertension, cardiovascular and kidney diseases